GlassScriptPhysician profile
Paul Scott
NPI 1528161924
$7,596.78
in general payments reported to CMS, 2019-2025
47 companies · $2,534 in 2025
The $2,534 reported for 2025 was more than what 84% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $517 · 2021: $517 · 2022: $2,015 · 2023: $549 · 2024: $549 · 2025: $2,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,970 · Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,969.74 |
| Food and Beverage | $1,663.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $2,010.51 | 2022-2025 | Biodfactor |
| Intuitive Surgical, INC. | $1,338.89 | 2019-2022 | |
| Astellas Pharma US INC | $537.45 | 2019-2023 | Xtandi |
| Janssen Biotech, INC. | $378.57 | 2019-2025 | Erleada, Akeega, Balversa |
| Boston Scientific Corporation | $332.25 | 2019-2024 | Lithoclast |
| Bayer Healthcare Pharmaceuticals INC. | $282.68 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $226.38 | 2019-2023 | Aveed, Xiaflex |
| Urogen Pharma, INC. | $221.29 | 2022-2025 | |
| Medtronic, INC. | $213.48 | 2023-2024 | Interstim |
| Dendreon Pharmaceuticals LLC | $188.35 | 2022-2025 | Provenge |
| Sumitomo Pharma America, INC. | $180.76 | 2023-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $173.28 | 2024-2025 | Aquabeam System |
| Olympus America INC. | $125.34 | 2020 | |
| Axonics, INC. | $116.31 | 2021 | |
| Pfizer INC. | $114.85 | 2019-2023 |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.